Rigshospitalet to evaluate CERAMENT' platform for use in bone tumors
LUND, Sweden, Jan. 7, 2016 /PRNewswire/ --BONESUPPORT', an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that the Company has signed a research collaboration with Rigshospitalet, Copenhagen University Hospital, the largest hospital in Denmark, whereby the institution will evaluate BONESUPPORT's platform technology, CERAMENT', in the management of bone tumors.
The study will retrospectively evaluate clinical results using bone allografts, and prospectively evaluate clinical results using CERAMENT'lBONE VOID FILLER and gentamicin eluting CERAMENT'lG, for prophylactic use in bone tumor patients. CERAMENT' will also be evaluated in combination with different substances in order to achieve enhancedbone healing.
Surgical management of bone tumors can create a residual bone defect in highly compromised patients, which requires void filling to prevent infection or fracture. Synthetic bone substitutes offer significant advantages over traditional autograft and allograft, which are associated with high morbidity and risk of disease transmission.
"We are excited to evaluate the CERAMENT' technology platform in this research collaboration," said Michael Moerk Petersen, Professor,MD, DMSc, Rigshospitalet, who will oversee the study. "Both autologous bone and allograft have some disadvantages and risks associated with their use. We believe CERAMENT' can provide a safe and effective alternative long-term solution to these technologies."
"BONESUPPORT' is pleased to enter into this collaboration with such a prestigious medical institution," said Dr. Eva Lidén, VP of Research and Development of BONESUPPORT'. "Our CERAMENT' technology platform continues to gain momentum with the physician community in Europe, and we will continue to invest in important research to validate our technology and improve upon the standard of care."
CERAMENT'|G is CE-mark approved and is commercially available in parts of Europe, SE Asia and the Middle East. CERAMENT'|BONE VOID FILLER is FDA cleared and CE-mark approved and is commercially available in the U.S., Canada, parts of Europe, SE Asia and the Middle East. Zimmer Biomet is the exclusive distributor of CERAMENT'|BONE VOID FILLER in the U.S.
About BONESUPPORT'
BONESUPPORT' is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications.CERAMENT'is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT'|G and CERAMENT' V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT'|Gand CERAMENT' V are not available in the United States.
CERAMENT' is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENT' is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT' spans more than eleven years. Over fifty pre-clinical, and clinical studies have been conducted and more than 20,000 patients have been treated with CERAMENT'. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT' please visitwww.bonesupport.com.
Investor and Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Offer.Nonhoff@bonesupport.com
Phone+46 46 286 53 60
PR0485-01 en
